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Telomeres are specialized structures at the ends of all eukaryotic chromosomes and have 
special biological functions. They protect chromosomes from nucleolytic degradation, end-
to-end fusions, and to be recognized as damaged DNA. Telomeres also contribute to the 
functional organizations of the chromosomes within the nucleus, participate in the 
regulation of gene expression, and most importantly, they serve as a molecular clock that 
controls the replicative capacity of the cells (Allsopp et al., 1992; Bailey et al., 2006; Chan & 
Blackburn, 2004; Hahn, 2005; O’sullivan & Karlseder, 2010). 
In the last decade substantial progress has been made in human telomere biology. Humans, 
like other vertebrates, have telomeres composed of repetitive 5’-TTAGGG-3’ sequences 
(Meyne et al., 1989; Moyzis et al., 1988). Human telomeres end in a 3’ overhang composed of 
TTAGGG track which is 50-500 nucleotides long (Huffman et al., 2000; Makarov et al., 1997; 
Wright et al., 1997). Electron microscopy studies of the psoralen cross-linked human 
telomeres have revealed that telomeres terminate in a lariat-like structure termed a t-loop. 
Binding of TRF1 and single stranded binding protein suggested that this structure is formed 
by invasion of the 3’ telomeric overhang into the duplex telomeric repeat array (Griffith et 
al., 1999) (Figure 1A and 1B). The fundamental aspect of the t-loop is thought to be the 
sequestration of the chromosome ends thereby providing a solution for the telomere end 
protection problem (de Lange, 2006; Grifith et al., 1999). Indeed, disruption of t-loop can 
result in telomere dysfunction and induce DNA damage response (d’Adda di Fagagna et al., 
2003). Human telomeric DNA is found as associated with nucleosomes, six-subunit protein 
complex called shelterin, and a number of other chromosomal factors that are not part of the 
shelterin (de Lange, 2005, 2006; Diotti & Loayza, 2011).  
1.1 Shelterin 
Shelterin complex represses DNA damage signaling responses at the chromosome ends. It 
also participates in the formation of t-loops and regulation of telomere length (de Lange, 
2005, 2006; Palm & de Lange, 2008) (Figure 1A and 1B). This complex consists of six subunits 
including TRF1, TRF2, TIN2, Rap1, POT1, and TPP1. The expression of shelterin is 
ubiquitous and it is present at telomeres throughout cell cycle. It is estimated that hundreds 
of copies of shelterin are found throughout the double stranded telomeric DNA and unlike 
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other telomere associated non-shelterin proteins; its function is limited only to telomeres (de 
Lange, 2005, 2006; Takai et al., 2010). 
Shelterin binds to double stranded telomeric DNA via its DNA binding proteins TRF1 
(TTAGGG-repeat-binding factor 1) and TRF2 (TTAGGG-repeat-biding factor 2) (Broccoli et 
al., 1997; Chong et al., 1995). TRF1 is the first identified subunit of shelterin complex that 
particularly binds to the double stranded telomeric DNA mainly as a dimer form that is 
mediated by its TRF homology (TRFH) domain (Bianchi et al., 1997; Zhong et al., 1992). The 
TRFH domain also participates in the recruitment of other proteins to the telomere (Y. Chen 
et al., 2008). In the shelterin complex TRF1 interacts only with TIN2 (S.H. Kim et al., 1999). In 
telomerase-positive mammalian cells, TRF1 works as a negative regulator of telomere length 
(Iwano et al., 2004; Okamoto et al., 2008) and supporting of this, the absence of TRF1 from 
telomeres results in telomere elongation (Iwano et al., 2004; Smith & de Lange, 2000; 
Smogorzewska et al., 2000; van Steensel & de Lange, 1997).  
TRF2, which is a 500 amino acid protein, shows sequence similarity to TRF1. Like TRF1, 
TRF2 also has a TRFH domain allowing its homodimerization (Broccoli et al., 1997; Fairall et 
al., 2001). It has been demonstrated that the TRF2 facilitates the t-loop formation in vitro 
(Stansel et al., 2001). TRF2 interacts with other three members of the shelterin complex,TIN2, 
Rap1, and POT1, and behaves as a negative regulator of telomere length (Smogorzewska et 
al., 2000; Smogorzewska & de Lange, 2004; Palm & De Lange, 2008). Both TRF1 and TRF2 
are subject to post-translational modifications including phosphorylation, SUMOylation, 
and PARsylation; however, the functional consequences of these modifications have yet to 
be clarified (Palm & de Lange, 2008). 
TIN2 (TRF1-interacting nuclear protein), which is a relatively small protein molecule, 
associates with TRF1 via its innermost region and at the same time it interacts with TRF2 
and TPP1 through its amino terminal domain (S.H. Kim et al., 1999; Palm & de Lange, 2008). 
Since TIN2 is located in the middle part of the shelterin complex, it can function as a bridge 
that connects the double stranded telomeric DNA binding proteins to those bind to the 
single stranded telomeric DNA (S.H. Kim et al., 1999, 2004; Ye et al., 2004a). Rap1 (repressor 
⁄ activator protein 1) is incorporated to the shelterin complex through binding to the TRF2 in 
approximately 1:1 ratio, and therefore, its presence on telomeres is TRF2 dependent (B. Li et 
al., 2000; Takai et al., 2010). Rap 1 plays an important role in telomere length regulation and 
it is thought that the Rap1 may be important for protective function of shelterin (de Lange, 
2005, 2006). 
TPP1 (POT1-TIN2 organizing protein, PTOP, PIP1,TINT1 ), both increases DNA binding 
activity of POT1 and it also connects POT1 to TIN2 by means of both its POT1 interaction 
and TIN2 interaction domains (Hockemeyer et al., 2007; D. Liu et al., 2004; Loayza et al., 
2004; Ye et al, 2004a; Ye et al., 2004b). The last member of the shelterin complex called POT1 
(protection of telomeres 1) was identified in the database through its homology with the 
DNA binding domain of TEBPα. Similar to TEBPα, POT1 binds to single stranded telomeric 
sequences by its two OB fold domains (Baumann & Cech, 2001). It has been shown that the 
POT1binds to single stranded TTAGGG, and it has been predicted that it can bind telomeric 
sequences both at the 3’ single stranded end and the displaced TTAGGG repeats at the base 
of the t-loop, called D-loop (Loayza et al., 2004). POT1 has a fundamental role in telomere 
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length regulation, since it functions as a terminal transducer of telomere length control 





Fig. 1. A. Schematic representation of human shelterin complex composed of six protein 
subunits: TRF1, TRF2, Rap1, TIN2, TPP1 and POT1. B. Illustration of t-loop structure of 
human telomeres accomplished by shelterin complex. Known/candidate negative and 
positive regulators of the human telomerase enzyme are shown as red and green 
rectangulars, respectively. Blue lines show the possible effects of candidate proteins 
determined in our study (Gümüş-Akay et al., 2009).  
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1.2 Non-shelterin telomeric proteins 
In addition to the shelterin complex, human telomeres consists of a large number of other 
proteins including Ku70/80, XPF/ERCC1, Apollo, the MRN complex, RecQ helicases, 
Tankyrase, and PINX1. Unlike shelterin complex that is located at telomeres throughout the 
cell cycle, these non-shelterin proteins only transiently associate with chromosome ends 
(Palm & de Lange, 2008). These proteins interact with the shelterin complex mainly by 
associating with TRF1 and TRF2. All of the non-shelterin telomere associated factors 
mediate telomere function in chromosome stability and contribute to telomere length 
regulation (de Lange, 2006; Palm & de Lange, 2008). 
2. Structure of human telomerase enzyme 
In human somatic cells, telomeres are approximately 10 kb long (Allshire et al., 1989; de 
Lange et al., 1990; Harley et al., 1990; Moyzis et al., 1988) and gradually shorten ~50-300 bp 
per cell division because of the end replication problem  and post replicational processing 
by exonuclease that degrades telomere strand at the 5’-end (Huffman et al., 2000; Makarov 
et al., 1997; Olovnikov, 1973). If this telomere erosion is not balanced by elongation, 
telomeres will progressively shorten; eventually lead to genomic instability and cell death. 
Hence, the long-term proliferation of human cells requires mechanisms to counteract 
telomere attrition that occurs in each cell division. The most widely used way for telomere 
maintenance is based on the enzyme called telomerase which was discovered by Carol 
Greider and Elizabeth Blackburn in 1984 (Greider & Blackburn, 1985). Nobel Prize in 
Physiology or Medicine 2009 was awarded to Elizabeth Blackburn, Carol Greider and Jack 
Szostak for the discovery of how chromosomes are protected by telomeres and the enzyme 
telomerase (http://nobelprize.org/nobel_prizes/medicine/laureates/2009/).  
Telomerase is a specialized reverse transcriptase that uses its RNA template to elongate the 
telomeres by addition of 5’-TTAGGG-3’ repeats to the terminal 3’ overhang (Greider & 
Blackburn, 1985). Human telomerase enzyme is composed of two core subunits involving 
RNA subunit (hTR) and catalytic telomerase reverse transcriptase (hTERT). In addition to 
these main components, studies have identified several telomerase-associated proteins 
required for proper functioning in vivo; such as dyskerin, hNop10, hGar1, that are potential 
components of the holoenzyme complex (Cristofari & Lingner, 2006; Shay et al., 2001). 
Telomerase components show significant size and sequence diversity among different 
species especially in the RNA moiety. However, certain parts of both subunits seem to be 
functionally conserved during evolution. 
2.1 hTR 
Human telomerase uses single stranded RNA as a template for de novo telomeric repeat 
synthesis. hTR is encoded by the hTERC gene located on chromosomal region 3q26 (Feng 
et al., 1995; Soder et al., 1997) . This gene is transcribed by RNA pol II. hTR is 451 
nucleotide long RNA and shows unique secondary structure with four special structural 
and functional domains, namely the pseudoknot domain, the CR4/CR5 domain, the 
H/ACA scaRNA domain, and CR7 domain. These domains have discrete functions such 
as RNA binding, dimerization, and recruitment of telomerase to the telomeres. Moreover, 
they mediate interactions between the hTR and catalytic subunit, hTERT, and other 
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telomerase-associated proteins. Among functional domains only the core domain and 
CR4/CR5 domains are required for in vitro reconstitution of catalytically active 
telomerase with hTERT. The template region of hTR is about 1.5-2 times the TTAGGG 
repeat length allowing both its annealing of the 3’ overhang and addition of telomeric 
repeats at the ends of chromosomes. Boundary element prevents reverse transcription 
beyond the 5’ boundary of the template (J.L. Chen et al., 2000; J.L.Chen & Greider, 2006; 
Cristofari & Lingner, 2006; Zhang et al., 2011). 
2.2 hTERT  
hTERT is encoded by hTERT gene located at 5p15.33 (Bryce et al., 2000). This gene spans 
approximately 40 kb of the genome and contains 16 exons (Cong et al., 1999). hTERT gene 
produces alternative transcript variants with unknown biological functions (Kilian et al., 
1997). Unlike the hTR, sequence of the catalytic subunit of the human telomerase enzyme is 
conserved across species. hTERT has functional regions that can be grouped into four 
distinct domains: TERT N-terminal domain (TEN), TERT RNA binding domain (TRBD), the 
reverse transcriptase domain (RT), and the C-terminal extension (Mason et al., 2011). The 
TEN domain ,also known as the anchor domain of telomerase, potentially facilitates 
processivity of the enzyme by preventing enzyme-DNA dissociation during translocation 
and to promote realignment events that accompany each round of telomere synthesis 
(Wyatt et al., 2007). TRBD domain, located between TEN and RT domains, is implicated in 
telomerase ribonucloprotein assembly and RNA binding. This domain contains 
evolutionarly conserved CP, QFP, T, and VSR motifs required for CR4/5 binding in 
vertebrates (Bley et al., 2011) The central RT domain is the catalytic part of the enzyme and 
has seven evolutionarily-conserved RT motifs including 1, 2, A, B’, C, D, E motifs. This 
domain is organized as two subdomains namely fingers and palm. The TERT active site 
contains three conserved aspartic acids, one of which resides in motif A and the other two 
within motif C. These residues form a catalytic triad contributing directly in nucleotide 
addition (Lingner et al., 1997; Nakamura et al., 1997). The motifs located at the C-terminal 
domain are not well conserved and telomerase specific (Autexier & Lue, 2006; J.L. Chen and 
Greider, 2006; Cristofari & Lingner, 2006; Mason et al., 2011; Wyatt et al., 2010). This domain 
is essential for human telomerase function in vivo. It has been shown that the C-terminal 
domain plays an important role in the catalytic activity and processivity of the telomerase 
(Huard et al., 2003). 
3. Regulation of human telomerase activity 
During normal human development, telomerase activity should be strictly regulated to meet 
proliferative needs of specific cellular functions such as tissue repair, while at the same time 
preserving proliferative barriers against tumorigenesis. Significant research effort in the last 
two decades has provided important data for our understanding of the complex processes 
of the telomere length homeostasis and telomerase regulation. Telomerase activity is 
regulated at many levels including transcription, mRNA splicing, maturation, processing 
and nuclear localization of both hTR and hTERT subunits, post-translational 
modifications and correct folding of hTERT, assembly of ribonucleoprotein complex, and 
accessibility of the telomeres to the holoenzyme (Cong et al., 2002; Ćukušić et al., 2008). 
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However, regulation at the hTERT level, particularly at the transcription level, seems to be 
the primary and rate limiting step in the telomerase activity control (L. Liu et al. 2004; Shay 
et al., 2001)  
Several positive and negative regulators of the hTERT gene have been identified (Figure 
1B). Some of the positive regulators of the hTERT promoter are oncogene c-myc , the 
transcription factor Sp1, the human papillomavirus 16 (HPV 16) protein E6, and steroid 
hormones (e.g. estrogen) (Cong et al., 2002; Ćukušić et al., 2008; L. Liu et al., 2004). By 
means of microcell-mediated chromosome transfer studies, it has been shown that the 
normal somatic cells have transcriptional repressors that inhibits hTERT transcription. The 
chromosomal regions that contain genes encoding these repressors have been determined 
as 3p21.3 in renal cancer cell line RCC23, 3p12-21.1 in breast cancer cell line 21NT 
(Oshimura & Barrett, 1997), 10p15.1 in hepatocellular carcinoma cell line (Nishimoto et al., 
2001), and 6p in human papilloma virus immortalized keratinocyte cell line and cervical 
cancer cell line (Steenbergen et al., 2001; L. Liu et al., 2004). In addition to these 
chromosomal regions, certain factors have been demonstrated to repress telomerase 
activity including antiproliferation factors such as transcription factor Mad1, the tumor 
suppressor proteins p53, pRb, E2F, the Wilms’ tumor 1, the myeloid cell-specific zinc 
finger protein 2, and differentiation factors, such as interferon-gamma and transforming 
growth factor β (Cong et al., 2002; Ćukušić et al., 2008; L. Liu et al., 2004). In addition to 
the transcription factors, hTERT expression is also regulated epigenetically (Cong et al., 
2002; L. Liu et al., 2004).  
Apart from the mechanisms summarized above, telomerase is also regulated by the 
shelterin and non-shelterin proteins localized at the telomeres. This type of regulation 
based on the accessibility of telomere substrates to the enzyme, telomerase. Several 
studies have shown that shelterin may affect the telomerase action, particularly, as a 
negative regulator (Smogorzewska & de Lange, 2004; de Lange, 2005, 2006; Palm & de 
Lange, 2008) (Figure 1B). Shelterin recognizes telomere length via its ability to accumulate 
all along the double stranded telomeric DNA. The longer the telomeric DNA, the more 
shelterin complex associated with it. This results in a t-loop formation and decreases the 
chance of the telomerase to reach the telomeric end (de Lange, 2006; Smogorzewska & de 
Lange, 2004). All of the shelterin subunits behave as a telomere length regulator and their 
amount at telomeric DNA affects elongation of telomeres. For example, the absence of 
TRF1 from telomeres results in telomere elongation (Iwano et al., 2004; van Steensel & 
deLange, 1997), whereas increased amount of TRF1 on telomeres leads them to become 
shorter (van Steensel & deLange, 1997). Similarly, as telomeres get longer, the number of 
TRF2 on telomeres increases. It has been shown that the overexpression of TRF2 results in 
telomere shortening, implying TRF2 also can modulate telomere length (Smogorzewska et 
al., 2000).  
Since telomerase ribonucleoprotein functions on the single stranded 3’ overhang, shelterin 
complex should perform its negative regulatory functions at this place (de Lange, 2005, 
2006). POT1, which is the only member binding to the single stranded telomeric sequences 
plays an important role in the effect of shelterin on telomerase (de Lange, 2005, 2006). 
According to the counting model for telomere length regulation, POT1 is the key player that 
functions as a terminal transducer of telomere length control (Loayza & de Lange, 2003). 
When telomeres become elongated, they are occupied with more shelterin, thereby the 
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chance of POT1 to associate with single stranded 3’ overhang also increases, which in turn 
leads to blockage of telomerase (Figure 1B).  
While shelterin complex seems to be responsible for negative telomerase regulation 
(Smogorzewska & de Lange, 2004; de Lange, 2005; Palm & de Lange, 2008), unexpected 
results showed that the POT1–TPP1 complex may activate telomerase processivity (Tejera et 
al., 2010; Wang et al., 2007). In order to explain the two opposit functions of the TPP1-POT1 
complex, three-state model of telomere length regulation has been proposed by Wang et al. 
(2007). When POT1–TPP1 coat the 3’ end of the G-overhang, it makes the telomeres 
inaccesible to the telomerase. On the other hand, it has been suggested that the TPP1-POT1 
complex probably function together to positively recruit telomerase to telomeric ssDNA 
through the TPP1 OB fold (Xin et al., 2007). At second state, TPP1-POT1 are removed from 
their binding sites by an as yet unidentified mechanism such as post-translational 
modification and disruption of the shelterin complex. The POT1–TPP1 complex then act as a 
telomerase processivity factor during telomere elongation. As the telomere length reaches a 
certain threshold, the newly synthesized repeats bind shelterin complexes, and the 3’ end of 
the G-overhang is again bound by POT1–TPP1, thereby preventing telomerase action 
(Bianchi & Shore, 2008; Wang et al., 2007).  
As mentioned before, non-shelterin telomere associated factors mediate telomere function in 
chromosome stability and contributes to telomere length regulation. For example, poly-
ADP-ribose polymerase called tankyrase binds to TRF1 and adds ADP-ribose chain to the 
Glu residues located at the N-terminal domain of the protein. This post-translational 
modification leads to separation of TRF1 from telomeres. Therefore, tankyrase acts as a 
positive regulator of telomere length (Hsiao & Smith, 2008; Smith & de Lange, 2000). 
Another shelterin accessory factor PINX1, for instance, functions as a telomerase inhibitor 
and participates in TRF-1 mediated telomere length control (Soohoo et al., 2010; Zhou et al., 
2001). 
Unfortunately, the mechanisms involved in control of telomerase activity seem to be a big 
puzzle. It is clear that the understanding the mechanisms involved in telomere length and 
telomerase regulation, and identification of novel candidate molecules would certainly have 
implications for understanding the molecular basis and management of human cancers. We 
have determined the chromosomal localizations of putative unidentified telomerase 
activator(s) and/or repressor(s) by high resolution comparative genomic hybridization (HR-
CGH) in highly telomerase expressing gastric tumor samples. We have found that genomic 
imbalances including 1q+, 8p+, 8q+, 10q+, 17p-, and 20p+ are associated with the higher 
telomerase activity. Our results suggest that 1q24, 8p21-p11.2, 8q21.1-q23, 10q21-qter and 
20pter-p11.2 may contain putative telomerase activator(s), whereas the 17p12 region may 
harbor candidate telomerase suppressor(s) (Gümüş-Akay et al., 2009). 
WWP1 (WW domain containing E3 ubiquitin protein ligase 1) gene located at 8q21 seems to 
be a candidate telomerase regulator. It is known that the TGF-β (beta), inhibits positive 
regulatory effect of c-Myc on hTERT promoter by increasing Smad3 phosphorylation (H. Li 
et al., 2006a, 2006b). Komuro et al. (2004) have shown that WWP1 protein could block the 
transcriptional activities of TGF-β by inducing nuclear export of Smad7 and eventually 
enhancing degradation of TGF- β type I receptor through ubiquitination. Our results have 
suggested that increase in WWP1 gene copy number could have caused blockage of TGF-β-
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mediated hTERT repression. We have suggested that the POLB and MKP8 genes located at 
8p11.2 and 8p12, respectively, might be putative telomerase activators (Gümüş-Akay et al., 
2009). POLB encodes a DNA repair enzyme called β-pol which is an error-prone polymerase 
(Bergoglio et al., 2001; Canitrot et al., 2000). TEIF (Telomerase Transcriptional Element 
Interacting Factor) is one of the newly identified transcriptional activators of POLB gene. 
This transcription factor can also bind to the promoter region of hTERT and activates its 
expression. Transcriptional regulation of both POLB and hTERT by the same transcription 
factor and increased activity of these two enzymes in cancers suggest a functional link 
between β-pol and telomerase (Tang et al., 2004; Zhao et al., 2005). The MKP8 gene at 8p12 
encodes a mitogen-activated protein kinase phosphatase-8 that inhibits P38 by 
dephosphorylation (Vasudevan et al., 2005). It has been shown that the P38 bind to the 
hTERT promoter and repress its transcription (Chang et al., 2005). Therefore, MKP8 might 
be another putative telomerase activator. FGF8 encoding Fibroblast Growth Factor 8 is 
located at 10q24. Repression of FGF8 protein has been reported to be necessary for TGF- β 
mediated transcriptional suppression (Takayashiki et al., 2005). Our results have insinuated 
that the FGF8 might regulate telomerase activity via TGF- β pathway. 
4. Telomeres and telomerase in cancer 
Telomerase activity is undetectable in most normal human somatic cells. However, it is 
expressed during early development and remains fully active in specific germ-
line/embryonic stem cells and cancer cells (Hahn et al., 2005; N.W. Kim et al., 1994). In 
addition, modest levels of telomerase activity are determined in proliferative tissues with 
high renewal potential such as the bone marrow, skin, gastrointestinal tract and testis as 
well as in activated lymphocytes (Yui et al., 1998; K. Liu et al., 1999). Normal human somatic 
cells have a limited replicative potential and after 50-70 doublings they become senescent. 
This is known as the Hayflick limit (Hayflick & Moorhead, 1961). This raises the question of 
what is the mechanism accounting for the finite division capacity of normal somatic cells? 
Although the whole mechanism has yet to be understood, one of the main determinants of 
cellular replicative capacity is the progressive loss of telomeric repeats occurs in each cell 
division (Allsopp et al., 1992; Harley et al., 1990).  
At the Hayflick limit one or a few critically shorten telomeres, which lose their capping 
function and activate DNA damage checkpoints, trigger an irreversible growth arrest 
known as a Mortality stage 1 (M1). Senescence involves p53 and pRb pathways and leads to 
the termination of cell proliferation (Wright et al., 1989; Shay et al., 1991). Senescence, 
therefore, can be accepted as a tumor suppressor mechanism (Campisi, 2005). Cells that can 
bypass this replicative senescence by inactivation of important cell cycle checkpoint genes 
(e.g. p53) continue to divide and lose their telomeres further until reaching the crisis stage or 
Mortality stage 2 (M2) (Wright et al., 1989; Shay et al., 1991; Zou et al., 2004). Cells that are 
able to reactivate/up-regulate their telomerase enzyme can escape from crisis and become 
immortalized, which is generally believed to be a critical step in cancer progression 
(Counter et al., 1992; N.W. Kim et al., 1994; Shay & Bacetti, 1997; Shay & Wright, 2010) 
(Figure 2). Although most cancer cells (80-90%) express a high level of telomerase activity, 
the remaining uses alternative lengthening of telomeres (ALT) by recombination to maintain 
their immortality (Bryan & Reddel, 1997). 
 




Fig. 2. The telomere hypothesis of replicative senescence and cancer.  
Telomere length is maintained in germ cells and stem cells by active telomerase. In the 
absence of active telomerase enzyme one or a few critically shorten telomeres trigger an 
irreversible growth arrest known as a Mortality stage 1 (M1). Cells that can bypass this 
replicative senescence by inactivation of important cell cycle checkpoint genes (e.g. p53) 
continue to divide and lose their telomeres further until reaching the crisis stage or 
Mortality stage 2 (M2). Cells those are able to reactivate/upregulate their telomerase 
enzyme can escape from crisis and become immortalized. 
The pivotal role of telomere and telomerase biology in cancer has been well documented 
by means of cellular and animal models (Artandi & Depinho, 2000). In 1994, N.W. Kim et 
al. showed that telomerase could be detected in about 90% of all human tumors examined, 
and a couple of years later other groups have demonstrated that the hTERT transfected 
cells never show a growth arrest (Bodnar et al., 1998; Counter et al., 1998). After that time, 
the number of articles on telomeres, telomerase and cancer has increased tremendously. 
All of the studies indicate that telomerase activity is almost universally an essential 
requirement for cellular immortalization and unlimited proliferative characteristic of 
cancer cells. In many human primary cancers increased or up-regulated telomerase 
activity have been reported, and increased telomerase activity has also been demonstrated 
to be related to poor prognosis. Thus telomerase activity emerges as an attractive target 
for both cancer diagnosis and treatment (Artandi & Depinho, 2010; Donate & Blasco, 2011; 
Granger et al., 2002). 
4.1 Telomere dysfunction and its consequences in carcinogenesis 
As mentioned above, telomeres are critical for maintenance, protection and stabilization 
of linear chromosomes, enabling continuous cell division. In the absence of telomere 
maintenance mechanisms progressive telomere shortening is thought to be the major 
cause of replicative senescence. Critically shortened telomeres lose the protection of 
telomere-binding proteins, leading to telomere uncapping, and this is known as telomere 
dysfunction. In normal cells, telomere dysfuntion activates DNA damage checkpoint 
pathways, particularly p53 and RB pathways, leading to stable growth arrest or 
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programmed cell death called apoptosis (d’Adda di Fagagna et al., 2003; d’Adda di 
Fagagna et al., 2004; Zou et al., 2004). 
On the contrary, cells derived from tumors can divide indefinitely in culture by means of 
their tumor maintenance mechanisms, most prominently by telomerase. It has been shown 
that the dysfunctional telomeres can lead to chromosome fusions before the 
reactivation/upregulation of telomerase, which has been proposed as a mechanism of 
chromosome instability in cancers (Gisselson et al., 2001; Maser & Depinho, 2002; Murnane, 
2010). Comparative genomic hybridization techniques have demonstrated extensive focal 
amplifications and deletions in human cancers which are now known to harbor oncogenes 
and tumor suppressor genes, respectively. This raises the question whether these 
chromosomal loci contain genes that induce carcinogenesis or they are the consequences of 
the genomic instability seen in cancer cells. Copy number alterations comes from aCGH 
analyses of tumors from telomerase-deficient mice (TERC -/- p53+/-) have suggested that 
chromosome breakage-fusion-bridge process caused by telomere dysfunction might provide 
a major mechanism driving amplifications and deletions in human cancer genomes 
(reviewed in Artandi & Depinho, 2010). 
4.2 Telomerase as diagnostic and prognostic marker in cancer 
Even though morphological assessment remains the gold standard for cancer diagnosis, 
there has been continuous seeking for new molecular markers that are less subjected to 
evaluation bias (E. Hiyama & K. Hiyama, 2003). Given that both of its crucial role in the 
carcinogenesis process and its uniqueness to all types of cancers, analysis of telomerase 
activity has been anticipated as a diagnostic and/or prognostic marker for this disease.  
After the development of PCR-based telomerase assay called telomeric repeat amplification 
protocol (TRAP) by N.W. Kim et al. (1994), investigation of telomerase activity in different 
tumor tissues and their normal counterparts has become easier. TRAP assay can detect as 
few as 10 telomerase positive cells (Wright et al., 1995) in a variety of biological samples, 
including solid tissue samples (Gümüş-Akay et al., 2007), blood, urine (Hess & Highsmith, 
2002), fine needle asprites (E. Hiyama & K. Hiyama, 2004), ascites, and peritoneal washing 
fluids (Hess & Highsmith, 2002; Ozmen et al., 2008). In its original form, TRAP assay was 
not able to measure the telomerase activity quantitatively, and serial dilutions of the 
tissue extracts and use of internal control were recommended in each assay. However, 
modified and more user-friendly versions of this method have been developed to improve 
its sensitivity and quantitative detection of telomerase activity, including TRAP-ELISA 
(enzyme-linked immunosorbent assay) (Gonzalez-Quevedo et al., 2000; Wu et al., 2000), 
TRAP-ELIDA (enzymatic luminometric inorganic pyrophosphate detection assay) (Xu et 
al., 2001), and real-time TRAP assay (Shim et al., 2005). The main disadvantages of 
detecting telomerase activity by TRAP assay are the contamination of telomerase 
expressing normal cells with the tissue of tested and the possibility of presence of PCR 
inhibitors in some tissue extracts (E. Hiyama & K. Hiyama, 2002, 2003, 2004). To avoid 
false–positive results due to contamination of cell samples with lymphocytes, K. Hiyama 
et al. (1995) suggested using of 1000 cell equivalents of cell lysate per assay, since proteins 
extracted from 1000 adult lymphocytes do not show detectable telomerase activity. 
Nevertheless, this assay is an indispensable method enabling sensitive and quantitative 
measurement of the telomerase activity. 
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In addition to the TRAP assay that directly assesses the enzymatic activity, detection of 
transcript levels of hTERT or hTR by RT-PCR and detection of hTERT and hTR by in situ 
hybridization techniques are also used in telomerase investigations (Heaphy & Meeker, 
2011; E. Hiyama and K. Hiyama, 2002, 2003, 2004). Expression studies of both hTERT and 
hTR via RT-PCR allow quantitative measurement of these subunits, although mRNA levels 
of hTERT may not always correlate with telomerase activity due to alternative splicing 
variants and post-translational modifications of this subunit and hTR is constitutively 
expressed in most of the cell types (Cong et al., 2002; Heaphy & Meeker, 2011). In situ 
hybridization studies of both hTERT and hTR enable detection and visualization of these 
subunits at single cell level, however, detection of transcripts does not always correlate with 
telomerase activity and quantitative analysis is almost imposable (Heaphy & Meeker, 2011; 
E. Hiyama and K. Hiyama, 2004). 
The increase in telomerase in cancer cells generally occurs very early during tumorigenesis; 
i.e. at the preneoplastic or in situ stage, telomerase activity may be useful for early detection 
of cancer, particularly in cytology samples. In some instances telomerase activity might not 
be very high, but it could show correlation with the tumor progression. Due to space 
limitations, here we focus predominantly on two types of malignancies that we had 
experiences: gastric and ovarian cancer. Readers who are interested in the clinical utility of 
telomerase in other types of cancer can find well-written articles in the literature. 
4.2.1 Telomerase in gastric cancer 
The prevalence of telomerase activity in gastric cancer has been reported as 70-98% (C.H. 
Chen and R.J. Chen, 2011). Telomerase activity in gastric lavage fluid has been suggested as 
a potential tumor marker that might help for early diagnosis of gastric cancer rate (S.C. 
Wong et al., 2006). Telomerase activity has also been reported in the peritoneal lavage of 
patients with gastric cancer and shown to be associated with advanced stages of the disease 
or peritoneal metastasis (Hu et al., 2009; Mori et al., 2000). Clinicopathological significance 
of telomerase activity in human gastric cancer is controversial. Some investigators have 
indicated that the telomerase activity in tumor tissues correlates well with depth of invasion 
and tumor differentiation (Usselmann et al., 2001; Yoo et al., 2003). On the other hand, other 
groups, similar to us, have shown no relation between clinical or histological factors and 
telomerase activity (Furugori et al., 2000; Gümüş-Akay et al., 2007; Kameshima et al., 2000). 
As mentioned before, although telomerase is repressed in most somatic cells, it can be 
detected in highly proliferative tissues. We have shown that in addition to the tumor 
samples (98%), normal gastric mucosa samples (95%) also show appreciable telomerase 
activity (Gümüş-Akay et al., 2007). According to our results, we suggest that if someone has 
to study the telomerase activity in tumors of such proliferative/regenerative tissues, care 
must be taken in order to make correct evaluations and telomerase activity should be tested 
in both tumor sample and their corresponding normal tissue sample obtained from the same 
patient. Moreover, we have experienced that the telomerase activity in tumor/normal 
tissues show great inter-individual variability. Therefore, it is difficult to set a general cut-off 
level of telomerase activity for gastric adenocarcinoma.  
The expression of catalytic subunit hTERT and the methylation status of its promoter have 
also been investigated in gastric cancer samples. Although it is highly expressed in tumor 
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tissues, there is a disagreement between the studies evaluating the usefulness of hTERT 
expression as a prognostic factor (Gigek et al., 2009; W. Li et al., 2008; Suzuki et al., 2000). It 
could be concluded that there is no a strict association between telomerase activity and 
staging or grading of disease with regard to all of information obtained by different research 
groups. This may explain why detection of telomerase activity have not reached the clinic in 
terms of predicting outcome for patients with gastric cancer. 
4.2.2 Telomerase in ovarian cancer 
In ovarian tumors, telomerase activity has been widely investigated among malignant, 
borderline, and benign lesions (Datar et al., 1999; Zheng et al. 1997). Studies have shown 
that telomerase activity is increased in about 74-100% of ovarian cancer subjects (C.H. Chen 
and R.J. Chen, 2011). Rate of telomerase activity in benign and borderline ovarian tumors 
have produced diverse results. It has been reported that the majority of cystadenomas do 
not show telomerase activity, while all borderline tumors express this enzyme (Wan et al., 
1997). In contrast, Yokoyama et al. (1998) have found that 40% of ovarian cystadenomas 
have telomerase activity. We have investigated the applicability of telomerase activity in 
detecting early recurrences of epithelial ovarian cancer after first-line chemotherapy (Ozmen 
et al., 2008). We have found that although mean telomerase activity was statistically higher 
in epithelial ovarian cancer patients than patients with benign disease, there was no relation 
between telomerase activity levels at second-look surgery and early recurrences of epithelial 
ovarian cancer. 
Buttitta et al (2003) have reported that an immunohistochemical study on archival tissue 
sections showing a moderate to strong nuclear hTERT staining in 86% of serous epithelial 
ovarian cancers. A significant correlation between hTERT expression and response to 
platinum-based chemotherapy has been documented in advanced epithelial ovarian cancer 
patients. However, the prognostic significance of hTERT in epithelial ovarian cancer is still 
uncertain. Similar to gastric cancer studies, some authors have reported that hTERT 
expression does not reflect the clinical outcome (Wisman et al., 2003 as cited in Gadducci et 
al., 2009; Widschwendter et al., 2004), whereas others have showed a poor survival for 
patients whose tumors displayed moderate to strong hTERT immunostaining (Brustmann, 
2005). It has been suggested that telomerase activity might only be used as a supplementary 
diagnostic procedure beside conventional pathological diagnosis. 
4.3 Telomerase as a target for cancer therapy 
Since most of the cancer cells and putative cancer stem or stem-like cells have appreciable 
telomorase activity (E. Hiyama & K. Hiyama, 2003; N.W. Kim et al., 1994; Shay & 
Bacchetti, 1997; Shay & Wright, 2010) to circumvent the telomere-dependent cellular 
senescence, inhibiting the telomerase activity by means of different approaches has 
emerged as potential cancer therapeutics. When compared to other cancer therapy 
strategies, anti-telomerase approaches seem to be more promising because of the 
following three main reasons. Firstly, unlike other molecular genetic changes, which show 
great differences in different types of cancers, telomerase can be accepted as a hallmark of 
all cancer types. Secondly, it is thought that cancer cells are less likely to develop 
resistance to anti-telomerase approaches than they are to other cancer targets. Finally, 
telomerase is a relatively specific cancer/cancer stem cell target because normal somatic 
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cells show slight or diminished telomerase activity and generally have longer telomeres. 
This reduces the probability of therapy- related toxicity to normal tissues. At present, two 
main telomerase targeting methodologies are presently in clinical trials: A direct 
inhibition of telomerase, and a number of active immunotherapy targeting against 
catalytic protein subunit hTERT. In addition to these strategies, agents blocking 
telomerase expression and biogenesis, telomere disrupting agents, and suicide gene 
therapy are also understudy (H. Chen et al., 2009; Harley, 2008).  
There has been several strategies that seek to inhibit telomerase activity at its expression and 
biogenesis levels, including, single-stranded antisense oligonucleoties and small-interfering 
RNAs that target hTERT mRNA and hTR (Folini et al., 2005; Glukhov et al., 1998; Kraemer 
et al., 2003; You et al., 2006 ), ribozyme cleavage of hTERT mRNA and hTR (Hao et al., 2003, 
2005; Lu et al., 2011) , expression of dominant-negative hTERT protein (Hahn et al., 1999), 
and Hsp90 inhibitors (Lee and Chung, 2010). However, agents belonging to this category 
may be more leaky, or less efficient than direct inhibitors. In addition, similar to the gene-
therapy based methodologies, this group of agents also has delivery and stability problems 
(Harley, 2008). 
Telomerase activity can also be inhibited by stabilizing the G-quadruplex structure of 
telomeres by G-quadruplex-interacting agents, like telomestatin (M.Y. Kim et al., 2002). This 
group of agents inhibits telomerase activity by fixing the single-stranded telomere substrate 
into a quadruplex structure so as to blocking telomere accessibility. Although several 
compounds in this class have demonstrated relatively rapid activity in human tumor 
xenograft studies in mice, their safety is under question, because they can also target 
endogenous telomeric sequences or G-rich sequences, which might be lethal for normal cells 
(Ogenasian & Bryan, 2007). Another telomerase based approach in cancer treatment is the 
hTERT promoter-driven cancer cell suicide. Because of its higher tumor specificity, stronger 
activity, and universal presence in cancel cells have made the hTERT promoter encouraging 
over other known promoters (Gu & Fang, 2003). Bax, caspase 8, and cytosine deaminase 
(CD) are among the suicide genes that have been used in hTERT promoter-driven cancer cell 
suicide (Gu et al., 2000; Komata et al., 2002; Yu et al., 2011). However, this methodology has 
not yet received clinical development support (Harley, 2008). 
Although gene therapy and antisense strategies have remarkable potential for the treatment 
of many human diseases, the practicability and clinical utility of these methodologies 
remain to be confirmed. One of the anti-telomerase approaches that seems to be more 
practical is the use of small-molecule inhibitors, such as reverse transcriptase inhibitors 
(Strahl & Blackburn, 1996), BIBR1532 {2-[(E)-3-naphtalen-2-yl-but-2-enoylamino]-benzoic 
acid}, and BIBR1591 {5-morpholin-4-yl-2-[(E)-3-naphtalen-2-yl-but-2-enoylamino]-benzoic 
acid} to the catalytic component hTERT (Damm et al., 2001). Another group of direct 
telomerase inhibitors, namely 2’-deoxy and 2’-substituted N-3’ P5’ NP oligonucleotides 
(NPS), have been identified, which binds to their complementary sequences on hTR. These 
oligonucleotides, unlike hTR antisense counterparts, do not activate RNase-H mediated 
degradation of the hTR. Instead, they inhibit telomerase activity through functioning as a 
template antagonist (Gryaznov et al., 2001; Shea-Herbert et al., 2002). GRN163 was 
developed in 2003 as a competitive telomerase inhibitor. This molecule hybridizes to hTR 
and represses primer binding to telomere It has been shown that GRN163 suppresses tumor 
growth without major toxicity (Asai et al., 2003). GRN163 has been further modified by 
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covalent lipid conjugation in order to improve its pharmacological properties, and named 
GRN163L. This compound is currently in multiple Phase-I and Phase-I/II clinical trials as 
potential broad-spectrum anticancer agent (Gryaznov, 2010). 
Because of its universal expression and fundamental function in cancer cells, TERT has been 
regarded as a self antigen useful for developing active telomerase immunotherapy/vaccine 
strategies. In this approach, TERT immunotherapy products are constructed to stimulate the 
immune system of the organism to damage and kill TERT expressing tumor cells. In order to 
achieve this, antigen-presenting cells (APCs) are subjected to peptide fragments or TERT 
coding gene products ex vivo or in vivo. Then, APCs cause an activation and propagation of 
TERT-specific T-cells that kill the cells displaying TERT peptides on their surfaces (Harley, 
2008; J.P. Liu et al., 2010). Vaccination with dendritic cells transfected with hTERT mRNA 
has been shown to induce strong immune responses to multiple hTERT epitopes and is 
therefore accepted as an attractive approach to more potent immunotherapy (Suso et al., 
2011). Clinical trials using telomerase immunotherapy/vaccine approaches involving 
GRNVAC1, GV1001, Vx001 have been very encouraging, and have involved several types of 
solid tumors and acute myeloid leukemia (Harley, 2008; Kotsakis et al., 2011; Suso et al., 
2011; Vetsika et al., 2011; Vonderheide, 2008).  
It is thought that in a well-designed clinical trial, if the p53 statuses of the patients are 
screened and those patients with an intact p53 are selected, better response rates to the 
telomerase inhibitors might be expected. On the other hand, tumors deficient for p53 would 
show high levels of genomic instability so as to gain resistance to other therapeutics in the 
regimen and could acquire ALT mechanism (K. K. Wong et al., 2006). Although ALT seems 
to be a potential resistance pathway to telomerase inhibitors, it is unlikely to be a major 
factor limiting the usefulness of telomerase inhibitors in a clinical setting (Shay & Wright, 
2006). The telomerase knockout mouse model has also demonstrated that absence of 
telomerase and associated telomere dysfunction enhance sensitivity to ionizing radiation 
and chemotherapeutic agents that generate double strand breaks. Therefore, it is suggested 
that one particularly attractive clinical trial design would be the potentially synergistic 
combination of telomerase inhibitors and radiation or break inducing agents (K. K. Wong et 
al., 2006). In support of this Ward & Autexier (2005) have shown that pharmacological 
inhibition of telomerase catalytic activity by BIBR1532 can sensitize cells to traditional 
etoposide, melphalan, and doxorubicin treatments in a telomere length-dependent fashion. 
Similarly, Incles et al. (2003) demonstrated that a G-quadruplex–interacting agent, BRACO-
19, sensitized parental and flavopiridol-resistant human colon carcinoma cell lines. 
There are several ongoing phase I and II clinical trials targeting telomerase activity, and 
phase III clinical trial has been recruited for pancreatic cancer. It is interesting that, none of 
them telomerase activity has not been used for exclusion or inclusion criteria for patient 
registration. It also reveals that more accurate, sensitive and robust test for telomerase 
activity has been requested.  
5. Conclusion 
Telomeres were first discovered in the 1930s, as the ends of linear chromosomes which have 
unique molecular structure that prevent end-to-end fusion of different chromosomes. 
Alexey Olovnikov reported in 1973 that the ends of human chromosomes could not replicate 
 
Telomere and Telomerase in Cancer: Recent Progress 
 
109 
by previously known replication machineries. This observation implied that cells had an 
enzyme that could lengthen telomeres. In 1984, Greider and Blackburn discovered that the 
enzyme telomerase has the ability to lengthen chromosomal ends by its reverse transcriptase 
activity. In 2009 Blackburn, Greider and Szostak were awarded the Noble Prize in 
Physiology or Medicine “for the discovery of how chromosomes are protected by telomeres 
and the enzyme telomerase”. 
Thousand studies have been published on telomeres and telomerase, and at the present time it 
is known that, they are essential for stability of genome as well as regulation of DNA repair 
pathways. The long and short of it is that they regulate cellular viability and proliferative 
capacity. Loss of telomerase in differentiated cells limits cell division, while reactivation of 
telomerase sustains proliferation and transformation. Cancer cells need a mechanism to 
maintain telomeres if they are going to divide indefinitely, and telomerase solves this problem. 
This precious function of telomerase causes itself to gain a unique role in cellular immortality 
and carcinogenesis. In many human primary cancers increased or up-regulated telomerase 
activity has been reported, and increased telomerase activity has also been demonstrated to be 
related to prognosis. The discovery of the central role of telomerase in cancer offer entirely 
new therapy alternatives targeting the telomeres and/or telomerase.  
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